Proto Labs, Inc. — Q1 2013 Form 10-Q
Reporting period: Three months ended March 31, 2013; compared with the three months ended March 31, 2012. Amounts are in U.S. dollars; financial statement amounts are in millions unless stated otherwise.
Business context
Proto Labs provides online, quick-turn CNC machining (Firstcut) and injection molding (Protomold) for prototypes and short-run production. It reported sales to approximately 3,500 existing customer companies, up 20% year over year, and approximately 700 new customer companies, broadly consistent with the prior-year period.
Financial performance and liquidity
- Revenue: $37.3 million, up 24.5%. Protomold revenue was $26.9 million, up 23.3%; Firstcut was $10.4 million, up 27.6%.
- Profit and margins: Gross profit was $23.3 million; gross margin was 62.4%, versus 59.1%. Operating income was $11.4 million, or 30.5% of revenue, versus $7.6 million, or 25.5%. Net income was $8.3 million versus $4.8 million; diluted EPS was $0.32 versus $0.22.
- Cash flow: Operating cash flow was $11.1 million, compared with $7.4 million. Investing used $25.3 million, primarily reflecting net purchases of marketable securities; financing provided $5.6 million. Cash and cash equivalents declined $8.8 million to $27.9 million.
- Liquidity: Short- and long-term marketable securities totaled $84.6 million. Cash plus marketable securities was approximately $112.5 million. Current assets were $94.2 million and current liabilities $14.0 million.
- Debt: Total reported debt obligations were approximately $0.5 million, including current and long-term portions.
- Other measures: The effective tax rate was 27.3%, versus 32.3%. Comprehensive income was $7.4 million; foreign currency translation reduced accumulated other comprehensive income by $0.9 million during the quarter.
Material changes versus Q1 2012
- Revenue growth was broad-based: U.S. revenue rose 26.9% and international revenue 17.6%. U.S. revenue represented 75.4% of sales, compared with 74.0%.
- Cost of revenue rose 14.6%, slower than revenue growth. Management attributed improved gross margin to higher equipment utilization and manufacturing efficiencies, with order growth exceeding capacity expansion through equipment purchases.
- Operating expenses increased 17.8% to $11.9 million. Research and development rose 58.3%, chiefly due to headcount and outside development services; marketing and sales rose 18.5%. General and administrative expense was approximately flat.
- Other income improved by $0.6 million year over year, primarily due to foreign-currency movements.
- Operating cash flow included a $4.1 million excess tax benefit from stock-based compensation, classified in financing activities in the cash flow statement. The 2012 comparison included $71.7 million of IPO proceeds; Q1 2013 did not.
Outlook, risks and unusual items
- No specific numerical revenue or earnings guidance was provided. Management expects cost of revenue to increase in dollars but remain relatively stable as a share of revenue, and expects continued investment in personnel, technology, marketing and research and development. It also expects public-company compliance and infrastructure costs to increase.
- The American Taxpayer Relief Act extended the research and development credit for 2012 and 2013. Proto Labs recognized a $0.3 million tax benefit in Q1 2013 related to the 2012 credit.
- International revenue was adversely affected by approximately $0.3 million from U.S. dollar strength. The company does not hedge foreign currency exposure; management stated a hypothetical 10% adverse exchange-rate change would not materially affect results.
- Management reported no material change to the risk factors in its 2012 Form 10-K, no litigation expected to have a material adverse effect, and no off-balance-sheet arrangements. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Whether strong revenue growth and the improvement in gross margin continue as capacity expands and production costs change.
- The sustainability of customer growth and the relative contributions from existing versus new customers and from international markets.
- Cash generation excluding the $4.1 million excess tax benefit and the impact of ongoing capital spending and securities purchases.
- The composition, maturities, credit quality and liquidity of the $84.6 million held-to-maturity securities portfolio, including the unrealized losses disclosed.
- Whether the lower effective tax rate, including the research and development credit benefit, is representative of future periods.